Imagine the day a machine can draw your blood, screen it for genetic mutations and chemical variations that can cause cancer, and pop out a drug tailor-made for your DNA.
That hypothetical drug would target – and fix - the point irregularities which have accumulated over time that can lead to the formation of tumors — and cancer. The National Institutes of Health have tapped the Viterbi School's Andrea Armani to develop a key instrument that takes researchers a step closer to realizing this vision.
In the DNA rendering to the left, two of the three strand of DNA are "normal;" however, the third strand has a region which can cause cancer. Professor Armani's research is focused on detecting these regions and understanding what events trigger the change in the DNA. The technique that she is using relies on a very sensitive nanolaser device which is shown in the electron microscope image to the right. The laser shown in this picture is smaller than the width of a human hair.
Armani has received the NIH’s 2010 New Innovator Award, which recognizes a select group of researchers with “exceptional creativity” and bold approaches that “have the potential to produce a major impact on broad, important problems in biomedical and behavioral research.”
The award amounts to a $2.3 million research grant over five years to investigate epigenetics. This field studies changes in DNA which are associated with cancer. Armani's study is entitled "Ultrasensitive Nanolasers for Epigenetics Investigations."
Analysis of these DNA changes has shown promise in the early detection and treatment of ovarian and other types of cancer, says Armani.
But current research methods are only able to capture snapshots of these DNA changes, instead of monitoring the process continuously. Therefore, they miss information that could be vital to understanding processes that have been linked to cancer and other diseases, like Huntington’s and diabetes.
The sensitivity or resolution of many of these techniques is also very poor. “It’s like trying to watch a TV show through static,” says Armani.
Her method will push the field straight to High-Definition.
Armani proposes to develop an ultrasensitive nanolaser that would allow her to detect changes in DNA as they’re happening in real-time. This device will also allow her to study a single DNA strand in isolation, rather than groups of hundreds to thousands of strands as researchers must do with current technology.
As DNA binds to the surface of the nanolaser, the “color” or lasing wavelength emitted by the laser will change. As the DNA changes, the color will change again. The improved resolution is a result of the precision with which the color can be monitored.
The first part of the project focuses on building the nanolaser instrument, while the second half funds the DNA experiments.
The goal? What Armani calls “un-doing” these triggers that can cause cancer.
She will focus first on using the nanolaser to perform initial proof-of-concept experiments using known triggers, such high concentrations of common solvents and cleaning agents.
Part of this process involves taking a single strand of DNA, exposing it to a harsh chemical and seeing whether a specific change is initiated. Ultimately she’d like to be able to warn people which triggers to avoid.
In the future, she plans to move the instrument to the Epigenome Center at the USC Keck School of Medicine and work with her collaborators there. “There are truly some of the world experts in this field at Keck, and I am looking forward to collaborating with them to explore the full potential of this instrument.”
Armani — and her lab, for that matter — is uniquely equipped to build this instrument; her postdoctorate work spanned both the chemical engineering and biology departments at the California Institute of Technology.
Armani joined the Viterbi School in 2008 as an assistant professor, and rapidly began adding awards and distinctions to an already distinguished resume. In 2009, Armani was named to MIT’s coveted TR35 list, which recognizes the world’s top 35 innovators under the age of 35.